* The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled st...
TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-sta...